Confirmed Participants include H Lundbeck, Janssen, Bayer, Sanofi and more for Drug Design 2015

SMi’s 14th annual Advances & Progress in Drug Design conference will take place on the 16th - 17th February 2015 in Marriott Regents Park Hotel, London, UK
 
 
Advances & Progress in Drug Design 2015
Advances & Progress in Drug Design 2015
LONDON - Jan. 5, 2015 - PRLog -- SMi’s upcoming event on Advances & Progress in Drug Design has been a premier conference in its field for more than a decade. During this period, there has been an ever-increasing interest in the application of computational biology tools, ranging from modelling and compound selection to drug repurposing and the calculation of mutation frequencies. The 14th instalment in the industry established conference will showcase innovative methodologies in drug design, provide strategies from theory into practice and offer practical guidance on drug design and discovery challenges.

A snapshot of the confirmed participants include: H Lundbeck, Janssen Research & Development, University of Cambridge School of Clinical Medicine, ZoBio BV, Bayer HealthCare, Sanofi-Aventis, Lead Pharma, plus many more.

Drug Design 2015 Will Aim To:

• Provide a forum for debate – An academic, industry and pharma viewpoint will be given in the panel debate led by Uppsala University, Chemical Computing Group and Janssen Research & Development. This conference provides the opportunity to discuss how computational and predictive tools have matured for the application of drug discovery.

• Present thoughts on best Practices – Share ideas with scientific leaders to identify cutting-edge developments including innovative ideas on modelling, creating focused mutant libraries for protein engineering and using integrate bioactivity information and gene expression data for mode-of-action analysis.

• Devise strategy – Hear case studies from major pharmaceutical companies and gain unique insights into applying structural bioinformatics to challenges in biotherapeutics drug discovery, strategies in building a robust technology pipeline for fragment based drug discovery, the development of novel highly selective Rho-kinase inhibitors and approaches in drug discovery used by MedImmune, Novartis, Astex Pharmaceuticals, Heptares and Sanofi.

• Look ahead at future advances – Discover the latest advances in structural biology and x-ray structures of target and anti-target kinases, steered molecular dynamics, GPCR rational design capabilities and x-ray crystallography.

• Allow peer to peer networking - Ample opportunity for discussion, including a sponsored drinks reception hosted by leading lifescience software solutions provider, Chemical Computing Group, 2 networking lunches, 2 morning coffees breaks and 2 afternoon teas.

For further information or to register please visit http://www.smi-online.co.uk/goto/2015drug-design7.asp

-------------------------- END --------------------------

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Media Contact
Teri Arri
tarri@smi-online.co.uk
+44 (0) 20 7827 6162
End
Source: » Follow
Email:***@smi-online.co.uk Email Verified
Tags:Pharmaceutical, Medical, Drug Design, Biology
Industry:Health, Science
Location:London - England - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share